These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers. Saliani M; Jalal R; Ahmadian MR Cancer Biol Med; 2019 Aug; 16(3):435-461. PubMed ID: 31565476 [TBL] [Abstract][Full Text] [Related]
24. A Breakthrough Brought about by Targeting KRAS Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550 [TBL] [Abstract][Full Text] [Related]
25. Defeat mutant KRAS with synthetic lethality. Pang X; Liu M Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838 [TBL] [Abstract][Full Text] [Related]
26. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo. Huang S; Ren X; Wang L; Zhang L; Wu X Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344 [TBL] [Abstract][Full Text] [Related]
30. More to the RAS Story: KRAS Lietman CD; Johnson ML; McCormick F; Lindsay CR Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303 [TBL] [Abstract][Full Text] [Related]
31. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design. Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268 [TBL] [Abstract][Full Text] [Related]
32. KRAS Oncogene Mutations in Colorectal Cancer Patients in a Nepalese Tertiary Care Hospital. Basnet BK; Gautam B; Ranabhat K; Paudel BD; Chapagain Acharya S; Bastola SR; Gyawali B J Nepal Health Res Counc; 2021 Dec; 19(3):504-507. PubMed ID: 35140422 [TBL] [Abstract][Full Text] [Related]
33. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895 [TBL] [Abstract][Full Text] [Related]
34. Challenges in Ras therapeutics in pancreatic cancer. Choi M; Bien H; Mofunanya A; Powers S Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065 [TBL] [Abstract][Full Text] [Related]
35. KRAS as a Therapeutic Target. McCormick F Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360 [TBL] [Abstract][Full Text] [Related]
36. KRAS Alleles: The Devil Is in the Detail. Haigis KM Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387 [TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in lung cancer. Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493 [TBL] [Abstract][Full Text] [Related]
38. Targeting KRAS in Non-Small Cell Lung Cancer. Corral de la Fuente E; Olmedo Garcia ME; Gomez Rueda A; Lage Y; Garrido P Front Oncol; 2021; 11():792635. PubMed ID: 35083149 [TBL] [Abstract][Full Text] [Related]
39. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Reck M; Carbone DP; Garassino M; Barlesi F Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836 [TBL] [Abstract][Full Text] [Related]
40. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age. Thng DKH; Toh TB; Chow EK Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]